I maintain a Hold rating on Praxis Precision Medicines, Inc., driven by positive open-label Radiant data for vormatrigine in epilepsy but tempered by clinical risks. Vormatrigine achieved a 56.3% ...
BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Hosted on MSN
Praxis Precision Medicines’ PRAX-628 Study: A Potential Game-Changer for Focal Seizures
Praxis Precision Medicines, Inc. ((PRAX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Praxis Precision Medicines Inc (NASDAQ:PRAX) shares jumped 4.83% in premarket trading to $56.70 after the company presented positive topline results from its RADIANT study for Vormatrigine on August 4 ...
BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback